Objectives: The Acute Cystitis Symptom Score (ACSS) was developed as a self-reporting questionnaire for clinical diagnosis of acute uncomplicated cystitis (AUC) and symptomatic changes in female patients. The aim of the present study was to assess the utility of the different domains of ACSS including the ‘dynamics' domain after therapy. The applicability of these domains in assessing changes in symptoms, as a function of time, in this population was investigated. Materials and Methods: During the validation process of the ACSS in Uzbek and Russian languages, a subgroup of patients (n = 63) returned after therapy and filled in part B of ACSS. Descriptive statistics were used, where suitable. Results: The reduction of typical symptoms and quality of life (QoL) assessment between first and follow-up visit correlated significantly with answers in the ‘dynamics' domain. Success/cure and non-success/failure could be clearly differentiated by the scores obtained in ‘typical' and ‘QoL' domains. Conclusion: The ACSS has proven to be a useful instrument to clinically diagnose AUC in women. It is also a suitable instrument for patient-reported outcome assessment, with applicability in both daily practice and in clinical studies. Slight modifications in the ‘dynamics' domain will even increase the applicability.

Keywords:
Cystitis, Female, Quality of life, Urinary tract infection, Acute Cystitis Symptom Score, Questionnaire, Patient-reported outcome
1.
Alidjanov JF, Abdufattaev UA, Makhsudov SA, Pilatz A, Akilov FA, Naber KG, Wagenlehner FM: New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: acute cystitis symptom score. Urol Int 2014;92:230-236.
2.
Cronbach LJ: Test reliability; its meaning and determination. Psychometrika 1947;12:1-16.
3.
Wilcoxon F: Individual comparisons by ranking methods. Biometrics Bull 1945;1:80-83.
4.
Student: The probable error of a mean. Biometrika 1908;6:1-25.
5.
Rosenthal R, Rosnow RL: Essentials of Behavioral Research: Methods and Data Analysis, ed 2. New York, McGraw-Hill, 1984.
6.
Henry DC Jr, Bettis RB, Riffer E, Haverstock DC, Kowalsky SF, Manning K, Hamed KA, Church DA: Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther 2002;24:2088-2104.
7.
Stamm WE, Counts GW, Running KR, Fihn S, Turck M, Holmes KK: Diagnosis of coliform infection in acutely dysuric women. N Engl J Med 1982;307:463-468.
8.
Hooton TM, Roberts PL, Cox ME, Stapleton AE: Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med 2013;369:1883-1891.
9.
Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE: Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious diseases society of America and the food and drug administration. Clin Infect Dis 1992;15(suppl 1):S216-S227.
10.
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious diseases society of America and the European society for microbiology and infectious diseases. Clin Infect Dis 2011;52:e103-e120.
11.
Grabe M, Bartoletti R, Bjerklund Johansen TE, Cai T, Çek M, Köves B, Naber KG, Pickard RS, Tenke P, Wagenlehner F, Wullt B: Guidelines on Urological Infections; Eau Guidelines, Edition Presented at the 30th EAU Annual Congress. Madrid, European Association of Urology, 2015, pp 1-78. http://uroweb.org/guideline/urological-infections/ (visited December 19, 2015).
12.
Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E: Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015;351:h6544.
13.
Ivanov D, Abramov-Sommariva D, Moritz K, Eskötter H, Kostinenko T, Martynyuk L, Kolesnik N, Naber KG: An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the management of uncomplicated urinary tract infections (uUTIs). Clin Phys 2015;1:1-11.
14.
Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D'Elia C, Malossini G, Boddi V, Bartoletti R: The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis 2012;55:771-777.
15.
Wagenlehner FM, Naber KG: Editorial commentary: treatment of asymptomatic bacteriuria might be harmful. Clin Infect Dis 2015;61:1662-1663.
16.
Cai T, Nesi G, Mazzoli S, Meacci F, Lanzafame P, Caciagli P, Mereu L, Tateo S, Malossini G, Selli C, Bartoletti R: Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. Clin Infect Dis 2015;61:1655-1661.
17.
US Department of Health and Human Services; Food and Drug Administration: Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. http://www.fda.gov/downloads/Drugs/.../Guidances/UCM193282.pdf (visited December 20, 2015).
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.